June 06th, 2023

HealthEquity, Inc. (Nasdaq: HQY) delivered impressive results in the first quarter of fiscal 2024, with an EPS of $0.50, surpassing the consensus estimate of $0.41.  Buoyed by this strong performance, the company has raised its outlook for th. Read more

June 05th, 2023

Raytheon Technologies Corporation (NYSE: RTX), doing business as Pratt and Whitney Military Engines, has been awarded a significant contract modification worth $2,023,073,136.  The modification, designated as P00015, is an extension of a prev. Read more

June 05th, 2023

Palantir Technologies Inc. (NYSE: PLTR) has been awarded a significant five-year indefinite-delivery/indefinite-quantity contract with a maximum ceiling of $463,000,000. The contract aims to provide ongoing capabilities and support for select units o. Read more

June 05th, 2023

GitLab Inc. (Nasdaq: GTLB) announced its financial results for the first quarter of fiscal 2024, reporting a loss of $0.06 per share. This figure was better than expected, surpassing the consensus estimate of a loss of $0.14 per share. Looking for. Read more

June 05th, 2023

Charges include operating unregistered exchanges, broker-dealers, and clearing agencies; misrepresenting trading controls and oversight on the Binance.US platform; and the unregistered offer and sale of securities. FOR IMMEDIATE RELEASE 2023-101 . Read more

June 05th, 2023

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) has entered into a binding agreement with Rafael Holdings, Inc. (NYSE: RFL).  Under the agreement, Rafael will acquire 4,000,000 shares of CYTH's common stock, along with warrants to purchase an additio. Read more

June 05th, 2023

Mallinckrodt plc (NYSE American: MNK) has made a significant disclosure in a regulatory filing with the U.S. Securities and Exchange Commission (SEC). The company has received unsolicited letters from various parties holding substantial positions acr. Read more

June 05th, 2023

Foghorn Therapeutics Inc. (Nasdaq: FHTX) has received positive news from the U.S. Food and Drug Administration (FDA) as the clinical hold on the Phase 1 monotherapy dose escalation study of FHD-286 in acute myelogenous leukemia (AML) and myelodysplas. Read more

June 05th, 2023

On Thursday, June 8, several companies are expected to report their financial results, including: DocuSign, Inc. (Nasdaq: DOCU), a prominent electronic signature and digital transaction management company, is scheduled to release its first quarter. Read more

June 05th, 2023

On Wednesday, June 7, several companies are anticipated to release their financial results, including: Verint Systems Inc. (Nasdaq: VRNT), a leading provider of customer engagement solutions, is set to announce its first quarter fiscal 2024 financ. Read more